Dianthus Therapeutics (DNTH) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed Travere Therapeutics (TVTX) over the past year, gaining 144.6% versus a gain of 109.6%. Over five years, TVTX leads with a +118.1% price change compared with -21.2% for DNTH. Travere Therapeutics is the larger company by market cap ($4.86 billion vs $4.56 billion), about 1.1 times the size.
Travere Therapeutics converts more of its revenue into profit, with a net margin of -5.2% versus -7973.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | TVTX |
|---|---|---|
| Share price | $81.51 | $51.59 |
| Market cap | $4.56B | $4.86B |
| 1-day change | -3.98% | -3.46% |
| YTD return | +105.97% | +39.86% |
| 1-year return | +144.61% | +109.57% |
| 5-year return | -21.17% | +118.12% |
| Forward P/E | — | 9.15 |
| EPS (TTM) | $-4.24 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | $490.73M |
| Revenue growth (YoY) | -67.35% | +110.45% |
| Net income (latest FY) | $-162.34M | $-25.55M |
| Gross margin | — | 97.89% |
| Operating margin | -8739.34% | -12.80% |
| Net margin | -7973.33% | -5.21% |
| 52-week high | $117.88 | $68.73 |
| 52-week low | $32.22 | $22.59 |
| Distance from 52-week high | -30.86% | -24.94% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +72.75% | +45.78% |
| Average volume | 821.22K | 1.58M |
| Shares outstanding | 55.93M | 94.26M |
| Employees | 92 | 497 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNTH has outperformed TVTX by 35.0 percentage points over the past year.
- Travere Therapeutics is more profitable, keeping -5.2 cents of every revenue dollar as net income versus -7973.3 cents for Dianthus Therapeutics.
- Travere Therapeutics grew revenue faster in its latest fiscal year (+110.45% vs -67.35%).
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees
DNTH vs TVTX FAQ
Which is bigger, Dianthus Therapeutics or Travere Therapeutics?
Travere Therapeutics (TVTX) is larger, with a market capitalization of $4.86B compared with $4.56B for Dianthus Therapeutics (DNTH).
Which stock has performed better over the past year, DNTH or TVTX?
DNTH returned +144.61% over the past 12 months, compared with +109.57% for TVTX (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and Travere Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.